Pulmonary Fibrosis - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis

The report reviews pipeline therapeutics for Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pulmonary Fibrosis therapeutics and enlists all their major and minor projects

The report assesses Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pulmonary Fibrosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AdAlta Pty Ltd.

Advinus Therapeutics Ltd

Aeolus Pharmaceuticals, Inc.

Afferent Pharmaceuticals, Inc.

Angion Biomedica Corp.

Apellis Pharmaceuticals Inc

Asahi Kasei Pharma Corp.

aTyr Pharma, Inc. ...

AdAlta Pty Ltd.

Advinus Therapeutics Ltd

Aeolus Pharmaceuticals, Inc.

Afferent Pharmaceuticals, Inc.

Angion Biomedica Corp.

Apellis Pharmaceuticals Inc

Asahi Kasei Pharma Corp.

aTyr Pharma, Inc.

Biogen Inc

Bioneer Corporation

BiOrion Technologies B.V.

Bristol-Myers Squibb Company

Celgene Corporation

Chrysalis Pharma SAS

Clanotech AB

Compugen Ltd.

Cynata Therapeutics Limited

Diffusion Pharmaceuticals Inc.

Digna Biotech, S.L.

Elsalys Biotech SAS

F. Hoffmann-La Roche Ltd.

FibroGen, Inc.

FibroStatin SL

Galapagos NV

Galectin Therapeutics, Inc.

GenKyoTex S.A.

GlaxoSmithKline Plc

Global Blood Therapeutics, Inc.

GNI Group Ltd.

HEC Pharm Co., Ltd.

Histocell S.L.

Hydra Biosciences, Inc.

iBio, Inc.

Immunomet Therapeutics, Inc.

Inventiva

Isarna Therapeutics GmbH

Kadmon Corporation, LLC

Kasiak Research Private Limited

KineMed, Inc.

Kolltan Pharmaceuticals, Inc.

Kyorin Pharmaceutical Co., Ltd.

Lpath, Inc.

Lung Therapeutics, Inc

miRagen Therapeutics, Inc.

Moerae Matrix, Inc.

MorphoSys AG

NicOx S.A.

Nitto Denko Corporation

Novartis AG

Nuevolution AB

Pharmaxis Limited

Pharmicell Co., Ltd.

Pluristem Therapeutics Inc.

Promedior, Inc.

ProMetic Life Sciences Inc.

Pulmatrix, Inc.

RedHill Biopharma Ltd.

Respira Therapeutics Inc

Rhizen Pharmaceuticals S.A.

Ribomic Inc.

Saje Pharma, LLC

Sanofi

Sirnaomics, Inc.

Sorrento Therapeutics, Inc.

SPR Biosciences LLC

Symic Biomedical, Inc.

TaiwanJ Pharmaceuticals Co., Ltd.

Terpenoid Therapeutics, Inc.

Teva Pharmaceutical Industries Ltd.

Therabron Therapeutics, Inc.

Vault Pharma Inc.

Vericel Corporation

Vicore Pharma AB

Yuhan Corporation

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Pulmonary Fibrosis Overview 7

Therapeutics Development 8

Pulmonary Fibrosis - Therapeutics under Development by Companies 10 ...

Table of Contents

Table of Contents 2

Introduction 6

Pulmonary Fibrosis Overview 7

Therapeutics Development 8

Pulmonary Fibrosis - Therapeutics under Development by Companies 10

Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes 16

Pulmonary Fibrosis - Pipeline Products Glance 17

Pulmonary Fibrosis - Products under Development by Companies 20

Pulmonary Fibrosis - Products under Investigation by Universities/Institutes 28

Pulmonary Fibrosis - Companies Involved in Therapeutics Development 29

Pulmonary Fibrosis - Therapeutics Assessment 103

Drug Profiles 118

Pulmonary Fibrosis - Dormant Projects 345

Pulmonary Fibrosis - Discontinued Products 352

Pulmonary Fibrosis - Product Development Milestones 353

Appendix 361

List of Tables

List of Tables

Number of Products under Development for Pulmonary Fibrosis, H2 2016 23

Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, ...

List of Tables

Number of Products under Development for Pulmonary Fibrosis, H2 2016 23

Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H2 2016 24

Number of Products under Development by Companies, H2 2016 25

Number of Products under Development by Companies, H2 2016 (Contd..1) 26

Number of Products under Development by Companies, H2 2016 (Contd..2) 27

Number of Products under Development by Companies, H2 2016 (Contd..3) 28

Number of Products under Development by Companies, H2 2016 (Contd..4) 29

Number of Products under Development by Companies, H2 2016 (Contd..5) 30

Number of Products under Investigation by Universities/Institutes, H2 2016 31

Comparative Analysis by Late Stage Development, H2 2016 32

Comparative Analysis by Clinical Stage Development, H2 2016 33

Comparative Analysis by Early Stage Development, H2 2016 34

Products under Development by Companies, H2 2016 35

Products under Development by Companies, H2 2016 (Contd..1) 36

Products under Development by Companies, H2 2016 (Contd..2) 37

Products under Development by Companies, H2 2016 (Contd..3) 38

Products under Development by Companies, H2 2016 (Contd..4) 39

Products under Development by Companies, H2 2016 (Contd..5) 40

Products under Development by Companies, H2 2016 (Contd..6) 41

Products under Development by Companies, H2 2016 (Contd..7) 42

Products under Investigation by Universities/Institutes, H2 2016 43

Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H2 2016 44

Pulmonary Fibrosis - Pipeline by Advinus Therapeutics Ltd, H2 2016 45

Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2016 46

Pulmonary Fibrosis - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016 47

Pulmonary Fibrosis - Pipeline by Angion Biomedica Corp., H2 2016 48

Pulmonary Fibrosis - Pipeline by Apellis Pharmaceuticals Inc, H2 2016 49

Pulmonary Fibrosis - Pipeline by Asahi Kasei Pharma Corp., H2 2016 50

Pulmonary Fibrosis - Pipeline by aTyr Pharma, Inc., H2 2016 51

Pulmonary Fibrosis - Pipeline by Biogen Inc, H2 2016 52

Pulmonary Fibrosis - Pipeline by Bioneer Corporation, H2 2016 53

Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2016 54

Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2016 55

Pulmonary Fibrosis - Pipeline by Celgene Corporation, H2 2016 56

Pulmonary Fibrosis - Pipeline by Chrysalis Pharma SAS, H2 2016 57

Pulmonary Fibrosis - Pipeline by Clanotech AB, H2 2016 58

Pulmonary Fibrosis - Pipeline by Compugen Ltd., H2 2016 59

Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Limited, H2 2016 60

Pulmonary Fibrosis - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016 61

Pulmonary Fibrosis - Pipeline by Digna Biotech, S.L., H2 2016 62

Pulmonary Fibrosis - Pipeline by Elsalys Biotech SAS, H2 2016 63

Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 64

Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H2 2016 65

Pulmonary Fibrosis - Pipeline by FibroStatin SL, H2 2016 66

Pulmonary Fibrosis - Pipeline by Galapagos NV, H2 2016 67

Pulmonary Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2016 68

Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H2 2016 69

Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H2 2016 70

Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics, Inc., H2 2016 71

Pulmonary Fibrosis - Pipeline by GNI Group Ltd., H2 2016 72

Pulmonary Fibrosis - Pipeline by HEC Pharm Co., Ltd., H2 2016 73

Pulmonary Fibrosis - Pipeline by Histocell S.L., H2 2016 74

Pulmonary Fibrosis - Pipeline by Hydra Biosciences, Inc., H2 2016 75

Pulmonary Fibrosis - Pipeline by iBio, Inc., H2 2016 76

Pulmonary Fibrosis - Pipeline by Immunomet Therapeutics, Inc. , H2 2016 77

Pulmonary Fibrosis - Pipeline by Inventiva, H2 2016 78

Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2016 79

Pulmonary Fibrosis - Pipeline by Kadmon Corporation, LLC, H2 2016 80

Pulmonary Fibrosis - Pipeline by Kasiak Research Private Limited, H2 2016 81

Pulmonary Fibrosis - Pipeline by KineMed, Inc., H2 2016 82

Pulmonary Fibrosis - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 83

Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 84

Pulmonary Fibrosis - Pipeline by Lpath, Inc., H2 2016 85

Pulmonary Fibrosis - Pipeline by Lung Therapeutics, Inc, H2 2016 86

Pulmonary Fibrosis - Pipeline by miRagen Therapeutics, Inc., H2 2016 87

Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H2 2016 88

Pulmonary Fibrosis - Pipeline by MorphoSys AG, H2 2016 89

Pulmonary Fibrosis - Pipeline by NicOx S.A., H2 2016 90

Pulmonary Fibrosis - Pipeline by Nitto Denko Corporation, H2 2016 91

Pulmonary Fibrosis - Pipeline by Novartis AG, H2 2016 92

Pulmonary Fibrosis - Pipeline by Nuevolution AB, H2 2016 93

Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H2 2016 94

Pulmonary Fibrosis - Pipeline by Pharmicell Co., Ltd., H2 2016 95

Pulmonary Fibrosis - Pipeline by Pluristem Therapeutics Inc., H2 2016 96

Pulmonary Fibrosis - Pipeline by Promedior, Inc., H2 2016 97

Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016 98

Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H2 2016 99

Pulmonary Fibrosis - Pipeline by RedHill Biopharma Ltd., H2 2016 100

Pulmonary Fibrosis - Pipeline by Respira Therapeutics Inc, H2 2016 101

Pulmonary Fibrosis - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 102

Pulmonary Fibrosis - Pipeline by Ribomic Inc., H2 2016 103

Pulmonary Fibrosis - Pipeline by Saje Pharma, LLC, H2 2016 104

Pulmonary Fibrosis - Pipeline by Sanofi, H2 2016 105

Pulmonary Fibrosis - Pipeline by Sirnaomics, Inc., H2 2016 106

Pulmonary Fibrosis - Pipeline by Sorrento Therapeutics, Inc., H2 2016 107

Pulmonary Fibrosis - Pipeline by SPR Biosciences LLC, H2 2016 108

Pulmonary Fibrosis - Pipeline by Symic Biomedical, Inc., H2 2016 109

Pulmonary Fibrosis - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016 110

Pulmonary Fibrosis - Pipeline by Terpenoid Therapeutics, Inc., H2 2016 111

Pulmonary Fibrosis - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 112

Pulmonary Fibrosis - Pipeline by Therabron Therapeutics, Inc., H2 2016 113

Pulmonary Fibrosis - Pipeline by Vault Pharma Inc., H2 2016 114

Pulmonary Fibrosis - Pipeline by Vericel Corporation, H2 2016 115

Pulmonary Fibrosis - Pipeline by Vicore Pharma AB, H2 2016 116

Pulmonary Fibrosis - Pipeline by Yuhan Corporation, H2 2016 117

Assessment by Monotherapy Products, H2 2016 118

Number of Products by Stage and Target, H2 2016 120

Number of Products by Stage and Mechanism of Action, H2 2016 125

Number of Products by Stage and Route of Administration, H2 2016 130

Number of Products by Stage and Molecule Type, H2 2016 132

Pulmonary Fibrosis - Dormant Projects, H2 2016 360

Pulmonary Fibrosis - Dormant Projects (Contd..1), H2 2016 361

Pulmonary Fibrosis - Dormant Projects (Contd..2), H2 2016 362

Pulmonary Fibrosis - Dormant Projects (Contd..3), H2 2016 363

Pulmonary Fibrosis - Dormant Projects (Contd..4), H2 2016 364

Pulmonary Fibrosis - Dormant Projects (Contd..5), H2 2016 365

Pulmonary Fibrosis - Dormant Projects (Contd..6), H2 2016 366

Pulmonary Fibrosis - Discontinued Products, H2 2016 367

List of Figures

List of Figures

Number of Products under Development for Pulmonary Fibrosis, H2 2016 23

Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, ...

List of Figures

Number of Products under Development for Pulmonary Fibrosis, H2 2016 23

Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H2 2016 24

Number of Products under Development by Companies, H2 2016 25

Number of Products under Investigation by Universities/Institutes, H2 2016 31

Comparative Analysis by Clinical Stage Development, H2 2016 33

Comparative Analysis by Early Stage Products, H2 2016 34

Assessment by Monotherapy Products, H2 2016 118

Number of Products by Top 10 Targets, H2 2016 119

Number of Products by Stage and Top 10 Targets, H2 2016 119

Number of Products by Top 10 Mechanism of Actions, H2 2016 124

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 124

Number of Products by Top 10 Routes of Administration, H2 2016 129

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 129

Number of Products by Top 10 Molecule Types, H2 2016 131

Number of Products by Stage and Top 10 Molecule Types, H2 2016 131

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports